These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1105 related articles for article (PubMed ID: 2453782)

  • 1. Augmentation of killer activity of murine spleen cells against allogeneic and syngeneic tumor cells by inoculation of alloantigen in vivo.
    Nishi Y; Hosokawa T; Aoike A; Kamahora T; Sudo H; Kawai K
    Microbiol Immunol; 1987; 31(12):1245-54. PubMed ID: 2453782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early development of CD8-negative and CD8-positive MHC-unrestricted cytotoxic cells induced by alloantigen inoculation in mice.
    Nishi Y; Hosokawa T; Aoike A; Kawai K; Kamahora T
    Microbiol Immunol; 1990; 34(9):775-85. PubMed ID: 2126592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of effector cells against B16 melanoma in mice inoculated with allogeneic spleen cells.
    Nishi Y; Hosokawa T; Aoike A; Han D; Takehara H; Kawai K; Kamahora T
    Microbiol Immunol; 1994; 38(3):217-23. PubMed ID: 7915815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosensitization in IL-2-containing limiting dilution cultures generates cytotoxic T lymphocytes (CTL) rather than LAK cells reactive with a syngeneic nonimmunogenic murine tumor.
    Leshem B; Epstein E; Kedar E
    Immunol Lett; 1989 Jan; 20(1):53-8. PubMed ID: 2785493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors.
    Sensi M; Grazioli L; Rodolfo M; Parmiani G
    Cancer Immunol Immunother; 1990; 31(1):37-43. PubMed ID: 2306754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-metastatic effect by in vivo administration of concanavalin A through augmentation of T-derived activated killer activity: efficacy to B16 melanoma expressed MHC antigen.
    Taniguchi K; Kawano YI; Toshitani A; Karashima A; Nomoto K
    Cell Immunol; 1989 May; 120(2):460-9. PubMed ID: 2785862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation.
    Saito M; Ichimura O; Kataoka M; Moriya Y; Ueno K; Sugawara Y; Nanjo M; Ishida N
    Cancer Immunol Immunother; 1986; 22(3):161-8. PubMed ID: 2425968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo antitumor activity of anti-CD3-induced activated killer cells.
    Yun YS; Hargrove ME; Ting CC
    Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The blocking activity of antisera raised to either tumor antigens or alloantigens in cytotoxicity assays using syngeneic or allogeneic killer cells on the P815 murine mastocytoma target.
    Al-Rammahy AK; Levy JG
    Cell Immunol; 1980 Dec; 56(2):338-46. PubMed ID: 6781763
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mononuclear phagocytes: a major population of effector cells responsible for rejection of allografted tumor cells in mice.
    Yoshida R; Takikawa O; Oku T; Habara-Ohkubo A
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1526-30. PubMed ID: 1996352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucyl-leucine methyl ester treatment of donor cells permits establishment of immunocompetent parent----F1 chimeras that are selectively tolerant of host alloantigens.
    Thiele DL; Calomeni JA; Lipsky PE
    J Immunol; 1987 Oct; 139(7):2137-42. PubMed ID: 3309052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive transfer of H-2-incompatible lymphokine-activated killer (LAK) cells: an approach for successful cancer immunotherapy free from graft-versus-host disease (GVHD) using murine models.
    Toshitani A; Taniguchi K; Himeno K; Kawano Y; Nomoto K
    Cell Immunol; 1988 Sep; 115(2):373-82. PubMed ID: 3409329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes.
    Nishimura T; Yagi H; Uchiyama Y; Hashimoto Y
    Cell Immunol; 1986 Jun; 100(1):149-57. PubMed ID: 2874890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P; Vourka-Karussis U; Weiss L; Slavin S
    J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of mouse natural killer cell activity by Lactobacillus casei and its surface antigens.
    Kato I; Yokokura T; Mutai M
    Microbiol Immunol; 1984; 28(2):209-17. PubMed ID: 6427563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural antitumor defense system of the murine liver.
    Cohen SA; Salazar D; von Muenchhausen W; Werner-Wasik M; Nolan JP
    J Leukoc Biol; 1985 May; 37(5):559-69. PubMed ID: 3856617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of natural killer (NK) cells in vivo with H-2 and non-H-2 alloantigens.
    Clark EA; Holly RD
    Immunogenetics; 1981; 12(3-4):221-35. PubMed ID: 7203558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.